Literature DB >> 10200732

Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

D G Robinson1, M G Woerner, J M Alvir, S Geisler, A Koreen, B Sheitman, M Chakos, D Mayerhoff, R Bilder, R Goldman, J A Lieberman.   

Abstract

OBJECTIVE: This study examined the treatment response of patients with first-episode schizophrenia and schizoaffective disorder and potential predictors of response.
METHOD: First-episode patients were assessed on measures of psychopathology, cognition, social functioning, and biological parameters and treated according to a standardized algorithm.
RESULTS: One hundred eighteen patients (52% male, mean age 25.2 years) entered the study. The cumulative percentage of patients responding by 1 year was 87%; the median time to response was 9 weeks. The following variables were significantly associated with less likelihood of response to treatment: male sex, obstetric complications, more severe hallucinations and delusions, poorer attention at baseline, and the development of parkinsonism during antipsychotic treatment. Variables not significantly related to treatment response were diagnosis (schizophrenia versus schizoaffective disorder), premorbid functioning, duration of psychotic symptoms prior to study entry, baseline disorganization, negative and depressive symptoms, baseline motor function, akathisia and dystonia during treatment, growth hormone and homovanillic acid measures, psychotic symptom activation to methylphenidate, and magnetic resonance measures.
CONCLUSIONS: Patients with first-episode schizophrenia and schizoaffective disorder have high rates of response to antipsychotic treatment; there are specific clinical and pathobiologic predictors of response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200732     DOI: 10.1176/ajp.156.4.544

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  99 in total

Review 1.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 2.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 3.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

4.  Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Authors:  Sébastien Urben; Pierre Baumann; Sandra Barcellona; Muriel Hafil; Ulrich Preuss; Claire Peter-Favre; Stéphanie Clarke; Olivier Halfon; Laurent Holzer
Journal:  Psychiatr Q       Date:  2012-09

5.  Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.

Authors:  Deepak K Sarpal; Miklos Argyelan; Delbert G Robinson; Philip R Szeszko; Katherine H Karlsgodt; Majnu John; Noah Weissman; Juan A Gallego; John M Kane; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2015-08-28       Impact factor: 18.112

Review 6.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

7.  Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.

Authors:  Saeed Farooq; Ofer Agid; George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2013-09-17       Impact factor: 9.306

Review 8.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

9.  Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome.

Authors:  Christoph U Correll; Julie B Penzner; Anne M Frederickson; Jessica J Richter; Andrea M Auther; Christopher W Smith; John M Kane; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2007-05-02       Impact factor: 9.306

10.  Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Authors:  Brian J Miller; Chelsea Bodenheimer; Krystle Crittenden
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.